326 related articles for article (PubMed ID: 30289108)
1. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
[TBL] [Abstract][Full Text] [Related]
2. SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death.
Song X; Ru M; Steinsnyder Z; Tkachuk K; Kopp RP; Sullivan J; Gümüş ZH; Offit K; Joseph V; Klein RJ
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1466-1472. PubMed ID: 35511739
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
Klein RJ; Hallden C; Gupta A; Savage CJ; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Wallström P; Vickers AJ; Lilja H
Eur Urol; 2012 Mar; 61(3):471-7. PubMed ID: 22101116
[TBL] [Abstract][Full Text] [Related]
4. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.
Gu C; Qu Y; Zhang G; Sun L; Zhu Y; Ye D
Oncotarget; 2015 Oct; 6(31):32205-11. PubMed ID: 26320190
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels.
Li W; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Melander O; Ulmert D; Lilja H; Klein RJ
Prostate; 2020 Dec; 80(16):1405-1412. PubMed ID: 32914890
[TBL] [Abstract][Full Text] [Related]
6. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging.
Grönberg H; Eklund M; Picker W; Aly M; Jäderling F; Adolfsson J; Landquist M; Haug ES; Ström P; Carlsson S; Nordström T
Eur Urol; 2018 Dec; 74(6):722-728. PubMed ID: 30001824
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide association study of serum prostate-specific antigen levels based on 1000 Genomes imputed data in Japanese: the Japan Multi-Institutional Collaborative Cohort Study.
Hishida A; Nakatochi M; Tamura T; Nagayoshi M; Okada R; Kubo Y; Tsukamoto M; Kadomatsu Y; Suzuki S; Nishiyama T; Kuriyama N; Watanabe I; Takezaki T; Nishimoto D; Kuriki K; Arisawa K; Katsuura-Kamano S; Mikami H; Kusakabe M; Oze I; Koyanagi YN; Nakamura Y; Kadota A; Shimanoe C; Tanaka K; Ikezaki H; Murata M; Kubo M; Momozawa Y; Takeuchi K; Wakai K;
Nagoya J Med Sci; 2021 Feb; 83(1):183-194. PubMed ID: 33727749
[TBL] [Abstract][Full Text] [Related]
10. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.
Bensen JT; Xu Z; Smith GJ; Mohler JL; Fontham ET; Taylor JA
Prostate; 2013 Jan; 73(1):11-22. PubMed ID: 22549899
[TBL] [Abstract][Full Text] [Related]
13. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.
Jeong BC; Chalfin HJ; Lee SB; Feng Z; Epstein JI; Trock BJ; Partin AW; Humphreys E; Walsh PC; Han M
Eur Urol; 2015 Feb; 67(2):342-6. PubMed ID: 24968968
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility loci associated with prostate cancer progression and mortality.
Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
16. A genome-wide pleiotropy scan for prostate cancer risk.
Panagiotou OA; Travis RC; Campa D; Berndt SI; Lindstrom S; Kraft P; Schumacher FR; Siddiq A; Papatheodorou SI; Stanford JL; Albanes D; Virtamo J; Weinstein SJ; Diver WR; Gapstur SM; Stevens VL; Boeing H; Bueno-de-Mesquita HB; Barricarte Gurrea A; Kaaks R; Khaw KT; Krogh V; Overvad K; Riboli E; Trichopoulos D; Giovannucci E; Stampfer M; Haiman C; Henderson B; Le Marchand L; Gaziano JM; Hunter DJ; Koutros S; Yeager M; Hoover RN; ; Chanock SJ; Wacholder S; Key TJ; Tsilidis KK
Eur Urol; 2015 Apr; 67(4):649-57. PubMed ID: 25277271
[TBL] [Abstract][Full Text] [Related]
17. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
[TBL] [Abstract][Full Text] [Related]
19. Replication study of 34 common SNPs associated with prostate cancer in the Romanian population.
Jinga V; Csiki IE; Manolescu A; Iordache P; Mates IN; Radavoi D; Rascu S; Badescu D; Badea P; Mates D
J Cell Mol Med; 2016 Apr; 20(4):594-600. PubMed ID: 26773531
[TBL] [Abstract][Full Text] [Related]
20. Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
Sooriakumaran P; Haendler L; Nyberg T; Gronberg H; Nilsson A; Carlsson S; Hosseini A; Adding C; Jonsson M; Ploumidis A; Egevad L; Steineck G; Wiklund P
Eur Urol; 2012 Nov; 62(5):768-74. PubMed ID: 22633365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
